We describe two unique real-world usage patterns of oritavancin, a single-dose antibiotic with no therapeutic monitoring requirements, in patients with SSTIs.

Oritavancin was administered to stable SSTI patients in the outpatient setting to avoid costly hospitalization for IV antibiotic treatment; hospital admissions 30 days after treatment were low.

In hospitalized patients with SSTIs, oritavancin was used to facilitate early hospital discharge; infection-related 30-day hospital readmissions were low.

The findings suggest that oritavancin may assist in avoiding hospitalization and facilitating early discharge in select SSTI patients.